Eli Lilly and Co. (LLY) Earns “Buy” Rating from Leerink Swann
Eli Lilly and Co. (NYSE:LLY)‘s stock had its “buy” rating restated by equities research analysts at Leerink Swann in a report issued on Sunday. They currently have a $103.00 target price on the stock. Leerink Swann’s target price would suggest a potential upside of 25.47% from the company’s current price.
Several other equities research analysts also recently commented on the stock. SunTrust Banks Inc. reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Wednesday, June 15th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Eli Lilly and in a report on Tuesday, June 28th. Jefferies Group upped their price objective on shares of Eli Lilly and from $100.00 to $105.00 and gave the company a “buy” rating in a report on Thursday, July 14th. BMO Capital Markets reaffirmed a “buy” rating and set a $94.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 27th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $93.00 price objective on the stock in a report on Friday, July 29th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Eli Lilly and currently has a consensus rating of “Buy” and a consensus target price of $97.06.
Shares of Eli Lilly and (NYSE:LLY) opened at 82.09 on Friday. The company’s 50 day moving average is $79.44 and its 200 day moving average is $77.49. Eli Lilly and has a one year low of $67.88 and a one year high of $88.16. The company has a market capitalization of $86.83 billion, a price-to-earnings ratio of 35.38 and a beta of 0.17.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/09/eli-lilly-and-co-lly-earns-buy-rating-from-leerink-swann-2.html
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.86. The company earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.90 earnings per share. Equities research analysts predict that Eli Lilly and will post $3.59 earnings per share for the current year.
In other news, insider Donald A. Zakrowski sold 1,213 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $79.54, for a total transaction of $16,703,400.00. Following the completion of the transaction, the insider now owns 126,220,804 shares in the company, valued at approximately $10,039,602,750.16. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of LLY. Iowa State Bank purchased a new position in shares of Eli Lilly and during the second quarter valued at about $104,000. PineBridge Investments L.P. raised its stake in shares of Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares during the last quarter. Cribstone Capital Management LLC acquired a new stake in shares of Eli Lilly and during the second quarter worth approximately $117,000. Coconut Grove Bank raised its stake in shares of Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares during the last quarter. Finally, Physicians Financial Services Inc. raised its stake in shares of Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares during the last quarter. Hedge funds and other institutional investors own 74.96% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.